In contrast, whilst the small proportion of patients on statin therapy had increased ApoA1 levels, ApoA1 was not affected by SLE-specific treatment, whereas GlycA was significantly increased in patients on prednisone and decreased in patients on hydroxychloroquine (Supplementary Fig. S3, available at Rheumatology online). Here, APOA1 is linked to systemic lupus erythematosus.